Darglitazone
![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C23H20N2O4S |
Molar mass | 420.48 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Darglitazone (previously known as CP 86325-2) is a member of the thiazolidinedione class of drugs and an agonist of peroxisome proliferator-activated receptor-γ (PPAR-γ), an orphan member of the nuclear receptor superfamily of transcription factors. It has a variety of insulin-sensitizing effects, such as improving glycemic and lipidemic control, and was researched by Pfizer as a treatment of metabolic disorders such as type 2 diabetes mellitus.[1]
Its development was terminated on November 08, 1999.[2]
Synthesis[]
![](http://upload.wikimedia.org/wikipedia/commons/thumb/c/c3/Darglitazone.png/220px-Darglitazone.png)
Synthesis of darglitazone
References[]
- ^ Hulin B, Clark DA, Goldstein SW, McDermott RE, Dambek PJ, Kappeler WH, et al. (May 1992). "Novel thiazolidine-2,4-diones as potent euglycemic agents". Journal of Medicinal Chemistry. 35 (10): 1853–64. doi:10.1021/jm00088a022. PMID 1588563.
- ^ "Drug Profile: Darglitazone". Adis Insight. Springer Nature Switzerland AG. Retrieved 28 November 2015.
Categories:
- Abandoned drugs
- Oxazoles
- Thiazolidinediones